A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections; Leukoencephalopathy, Progressive Multifocal
Intervention: Interferon alfa-2b (Drug); Zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Miami
Summary
To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating
progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.
Clinical Details
Official title: A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
Study design: Primary Purpose: Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- HIV seropositivity by both ELISA and Western blot.
- Biopsy proven progressive multifocal leukoencephalopathy (PML).
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Intolerant to interferon.
- Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis,
multiple sclerosis (MS), or neurosyphilis.
Patients with the following are excluded:
- Intolerant to interferon.
- Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis,
multiple sclerosis (MS), or neurosyphilis.
Prior Medication:
Excluded:
- Patients receiving interferon for other reasons.
Locations and Contacts
Univ of Miami School of Medicine, Miami, Florida 33136, United States
Additional Information
Last updated: June 23, 2005
|